Adriana Bajetto
Overview
Explore the profile of Adriana Bajetto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corsaro A, Tremonti B, Bajetto A, Barbieri F, Thellung S, Florio T
Expert Opin Ther Targets
. 2024 Nov;
28(11):937-952.
PMID: 39582130
Introduction: Glioblastoma is the most aggressive brain tumor, typically associated with poor prognosis. Its treatment is challenging due to the peculiar glioblastoma cell biology and its microenvironment complexity. Specifically, a...
2.
Camerino I, Franco P, Bajetto A, Thellung S, Florio T, Stoppelli M, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519339
Glioblastoma (GBM) is the most aggressive type of brain tumor, characterized by poor outcome and limited therapeutic options. During tumor progression, GBM may undergo the process of vasculogenic mimicry (VM),...
3.
Bajetto A, Pattarozzi A, Sirito R, Barbieri F, Florio T
Int Immunopharmacol
. 2023 Oct;
124(Pt B):111078.
PMID: 37844465
Metformin, a first-line drug for type-2 diabetes, displays pleiotropic effects on inflammation, aging, and cancer. Obesity triggers a low-grade chronic inflammation leading to insulin resistance, characterized by increased pro-inflammatory cytokines...
4.
Barbieri F, Bajetto A, Dellacasagrande I, Solari A, Wurth R, Fernandez V, et al.
Neuro Oncol
. 2023 Apr;
25(10):1775-1787.
PMID: 37074930
Background: Meningiomas are mainly benign brain tumors, although about 20% of histologically benign cases are clinically aggressive and recur after resection. We hypothesize that meningioma brain invasiveness and recurrence may...
5.
Viti F, Pramotton F, Martufi M, Magrassi R, Pedemonte N, Nizzari M, et al.
Biomater Adv
. 2023 Mar;
148:213355.
PMID: 36893487
Visceral myopathy (VSCM) is a rare genetic disease, orphan of pharmacological therapy. VSCM diagnosis is not always straightforward due to symptomatology similarities with mitochondrial or neuronal forms of intestinal pseudo-obstruction....
6.
Barbieri F, Bosio A, Pattarozzi A, Tonelli M, Bajetto A, Verduci I, et al.
J Exp Clin Cancer Res
. 2022 Feb;
41(1):53.
PMID: 35135603
Background: Chloride intracellular channel-1 (CLIC1) activity controls glioblastoma proliferation. Metformin exerts antitumor effects in glioblastoma stem cells (GSCs) inhibiting CLIC1 activity, but its low potency hampers its translation in clinical...
7.
Amaru J, Barbieri F, Arvigo M, Solari A, Bajetto A, Nista F, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33920241
First-generation somatostatin receptor ligands (fg-SRLs), such as octreotide (OCT), represent the first-line medical therapy in acromegaly. Fg-SRLs show a preferential binding affinity for somatostatin receptor subtype-2 (SST), while the second-generation...
8.
Bajetto A, Thellung S, Dellacasagrande I, Pagano A, Barbieri F, Florio T
Stem Cells Transl Med
. 2020 Jun;
9(11):1310-1330.
PMID: 32543030
Mesenchymal stem cells (MSCs) can be isolated from bone marrow or other adult tissues (adipose tissue, dental pulp, amniotic fluid, and umbilical cord). In vitro, MSCs grow as adherent cells,...
9.
Pastorino O, Gentile M, Mancini A, Del Gaudio N, Di Costanzo A, Bajetto A, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31146471
Glioblastoma (GBM), a high-grade glioma (WHO grade IV), is the most aggressive form of brain cancer. Available treatment options for GBM involve a combination of surgery, radiation and chemotherapy but...
10.
Barbieri F, Wurth R, Pattarozzi A, Verduci I, Mazzola C, Cattaneo M, et al.
Front Pharmacol
. 2018 Sep;
9:899.
PMID: 30186163
The antidiabetic biguanide metformin exerts antiproliferative effects in different solid tumors. However, during preclinical studies, metformin concentrations required to induce cell growth arrest were invariably within the mM range, thus...